Sign in

NCT07528443Completed

Ultraprocessed Foods in Colombia

Source: ClinicalTrials.gov · Last updated 3 Sept 2026

Brief summary (registry, in English)

The study seeks to examine how characters on packaging and warning labels affect purchase intentions and risk perception among children aged 12 to 17 in Colombia and, examine whether characters' presence weakens or reduces the perceived message effectiveness of the warning labels' impact. This will be a 2x2 between-subjects experiment manipulating presence or absence of characters and presence or absence of warning labels. Participants will be randomly assigned to 1 of 4 conditions in an online survey programmed in Qualtrics.

Status (registry)
Completed
Study type
Interventional
Enrollment
2000 (actual)
First submitted
7 Apr 2026
Start date
25 Jun 2026
Primary completion date
15 Aug 2026
Lead sponsor
University of North Carolina, Chapel Hill
Diseases
Obesity
NCT number
NCT07528443

What you commit to

  • Study type: Interventional
  • Participants enrolled: 2000
  • From 25 Jun 2026 to the primary completion date, 15 Aug 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Children with legal blindness, partial blindness, or total blindness, since the study involves viewing images and reading questions.

Who the study is looking for

  • Children and adolescents between 12 and 17 years old
  • Colombian residents

Age in the registry: 12 years to 17 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Online panel
Coordinator of this site? Confirm its status
BogotáColombiaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.